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Abstract
Background: The relationship between TB/HIV co-infection and common mental disorders (CMD) has been scarcely 
investigated. In this study, we compared the occurrence of CMD in TB/HIV co-infected and non-co-infected HIV 
patients in Ethiopia.
Methods: We conducted a cross sectional study in three hospitals in Ethiopia from February to April, 2009. The study 
population consisted of 155 TB/HIV co-infected and 465 non-co-infected HIV patients. CMD was assessed through face 
to face interviews by trained clinical nurses using the Kessler 10 scale. Several risk factors for CMD were assessed using 
a structured questionnaire.
Results: TB/HIV co-infected patients had significantly (p = 0.001) greater risk of CMD (63.7%) than the non-co-infected 
patients (46.7%). When adjusted for the effect of potential confounding variables, the odds of having CMD for TB/HIV 
co-infected individuals was 1.7 times the odds for non-co-infected patients [OR = 1.7, (95%CI: 1.0, 2.9)]. Individuals who 
had no source of income [OR = 1.7, (95%CI: 1.1, 2.8)], and day labourers [OR = 2.4, 95%CI: 1.2, 5.1)] were more likely to 
have CMD as compared to individuals who had a source of income and government employees respectively. Patients 
who perceived stigma [OR = 2.2, 95%CI: 1.5, 3.2)] and who rate their general health as "poor" [OR = 10.0, 95%CI: 2.8, 
35.1)] had significantly greater risk of CMD than individual who did not perceive stigma or who perceived their general 
health to be "good".
Conclusion: TB/HIV control programs should develop guidelines to screen and treat CMD among TB/HIV co-infected 
patients. Screening programs should focus on individuals with no source of income, jobless people and day labourers.
Background
The global burden of disease report revealed that neurop-
sychiatric conditions accounted for up to a quarter of all
the disability-adjusted life years lost[1]. In low and middle
income countries (LAMIC), neuropsychiatric disorders
such as depression, anxiety and somatoform disorders
account for 9.8% of the global burden of diseases[2].
The risk factors for mental health problems are com-
plex [3]. Poverty, low education, social exclusion, gender
disadvantage, conflict and disasters are the major social
determinants of mental disorders[2]. Presence of medical
illnesses [4] stigma and discrimination [5] also play a role
in the development of depression.
The recent Lancet series on global mental health high-
lighted the lack of research on the interactions between
mental disorders and communicable diseases such as
tuberculosis (TB) and HIV/AIDS in low income settings
[4]. A high rate of depressive disorders has been reported
among patients with HIV in high income countries. In
the United States, a higher rate of depressive disorders
was observed in HIV seropositive women (19%) than in
HIV seronegative women (4.8%)[6]. Bing and colleagues
[7] also reported that the 12-month prevalence of major
depression was 36% in HIV infected adults compared to
7.6% in the general population in the United States. Some
studies in LAMIC (Kenya, Democratic Republic of Congo
and Thailand) also revealed that the rate of depression
was higher in HIV seropositive patients than in HIV neg-
ative individuals [8].* Correspondence: amare_deribew@yahoo.com
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of the central nervous system and side effects of antiret-
roviral therapy (ART), especially the Efavirenz, may cause
mental health problems[4]. There is evidence that indi-
viduals with mental health problems are at higher risk of
contracting HIV due to their higher risk behaviours[9].
Adherence to ART is adversely affected by depres-
sion[10-12]. Moreover, depression may reduce the CD4
lymphocyte count, increase viral load and mortality in
patients with AIDS[13-15]. On the other hand, treatment
of depression has been found to improve health outcomes
in patients with HIV[14,15].
Some studies have investigated the relationship
between common mental disorders (CMD) and TB. A
study conducted in Turkey showed that the prevalence of
depression and anxiety was 19% for recently diagnosed
patients with TB, 22% for defaulted TB patients, and 26%
for patients with multidrug-resistant TB[16]. The preva-
lence of CMD in 53 Nigerian TB patients recruited in a
chest clinic was 30%, compared to 5% in healthy con-
trols[17]. A study done in Pakistan showed that the prev-
alence of depression and anxiety among TB patients was
43% and 47% respectively[18]. TB patients have poor
mental health and quality of life compared to the general
population in United Kingdom[19].
TB/HIV co-infection poses immense diagnostic and
economic challenges for developing countries[20]. HIV is
the strongest risk factor for the development of active
pulmonary and extra pulmonary TB. TB also accelerates
the deterioration of the immune status of patients with
HIV [21-24] and it is one of the leading causes of mortal-
ity in people living with HIV/AIDS (PLHA)[25]. In Ethio-
pia, the rate of TB/HIV co-infection ranges from 45% in
Addis Ababa[26] to 52% in North Ethiopia[27].
Although several studies have been done concerning
the interaction between either HIV/AIDS or TB with
mental health problems, little is known about the effect of
TB/HIV co-infection on common mental disorders.
CMD, characterized by a significant level of depressive,
anxiety and/or somatic symptoms are common among
women in Ethiopia[28,29]. So far the magnitude of CMD
among men and the interaction between CMD and com-
municable diseases has not been investigated in Ethiopia.
The objective of this study was to compare the occur-
rence of CMD in TB/HIV co-infected and non-co-
infected HIV patients in Ethiopia.
Methods
Study Settings and Population
From February to March, 2009, we conducted a cross sec-
tional study in three hospitals in Oromiya regional state
of Ethiopia. Based on the availability of patients, we
selected Adama, Nekemet and Jimma specialized hospi-
tals in the east, west and southwest part of Ethiopia
respectively. The methodology of this study is described
elsewhere[30]. In brief, the study population consisted of
155 TB/HIV co-infected and 465 non-co-infected HIV
patients. All TB patients in the first two months of TB
treatment were asked to participate in the study. For each
TB/HIV co-infected patient, 3 non-co-infected HIV
patients were also asked to participate. The latter were
selected using a simple random sampling technique using
the patients' unique identification number in the HIV
clinics. TB was diagnosed using national TB guide-
lines[31]. The non-co-infected patients were also
screened for the presence of any signs and symptoms of
TB. Non-co-infected HIV patients with a prior history of
TB were excluded from the study. Patients who were less
than 15 years old, had TB meningitis or another opportu-
nistic infection, had a chronic illness like diabetes, cardio-
vascular disease or hypertension were excluded from the
study.
Data collection procedures
CMD was assessed through face to face interviews by
trained clinical nurses using the Kessler 10 scale[32]
which consisted of 10 five-point Likert scale (0 = never, 1
= rarely, 2 = some of the time, 3 = most of the time, 4 = all
of the time) questions. For the diagnosis of CMD, the
Kessler 10 scale was validated in Ethiopia against a gold
standard of psychiatrists' diagnosis[28]. In a previous
study, two psychiatrists used the validated Comprehen-
sive Psychopathology Rating Scale (CPRS) to diagnose
CMD[29]. The CPRS has 66 items; 40 symptoms based
on the subjective report of the interviewee, 25 signs rated
on the basis of observation during the interview and a
global rating indicating presence of significant mental
disorder. The presence of clearly defined symptoms or
signs of mental disorder was rated on a 4-point scale (0-
3). The definitions of each scale point were standardized
as follows: 0 = not present; 1 = doubtful whether present,
and not interfering with life; 2 = definitely present and of
moderate severity; 3 = severe or incapacitating. The psy-
chiatrists were asked to conduct a full psychiatric inter-
view and then complete the CPRS ratings using all
available information[28,29]. Caseness of CMD was
determined on the basis of any of the combination of
depressive, anxiety and/or somatic symptoms present at
clinically significant level. At the cut-off point of 6/7, the
Kessler 10 scale had a sensitivity and specificity of 84.2%
and 77.8% respectively to diagnose CMD[28].
Perceived stigma was measured using a questionnaire
adopted from Berger et al[33]. The instrument was highly
reliable in a pre-test (Cronbach's α = 0.93). The stigma
scale consisted of four-point Likert scale (strongly dis-
agree, disagree, agree, strongly agree) questions concern-
ing perceived isolation, shame, guilt and disclosure of the
HIV status. Item scores of the stigma questions were
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pants were classified as having or not having perceived
stigma using the mean of the stigma variable as cut-off
point. Perceived general health of the participants (good,
medium and poor) was assessed by asking the question
'How would you rate your health?'
Medical charts were reviewed to collect clinical infor-
mation and level of adherence to antiretroviral and TB
treatment. Individuals who took more than 95% of the
prescribed doses were labelled as adherent to antiretrovi-
ral therapy.
Data Analysis
Data were analyzed using SPSS version 16.0 software.
Item scores of the Kessler scale were summed and indi-
viduals who scored above the cut-off point of 6/7
[28]were labelled as having CMD. The Pearson's chi-
square test was used to evaluate the association between
exposure variables (TB/HIV co-infection, socio-demo-
graphic and clinical characteristics of the patients) and
CMD. A stepwise logistic regression model was used to
adjust for the effect of confounding variables. Variables
significantly associated (P < 0.05) with CMD or TB/HIV
co-infection in the Pearson's chi-square test were
included in the logistic regression model.
Ethical consideration
Ethical clearance was obtained from the Jimma Univer-
sity ethical review board. Written informed consent was
obtained from the study participants. To ensure confi-
dentiality, we used codes to analyze the data.
Results
All of the 465 non-co-infected HIV patients and 124
(80%) of the co-infected HIV patients participated in the
study; 31 TB/HIV co-infected patients were lost to follow
up before interview. Of the co-infected patients, smear
negative, smear positive and extra pulmonary TB
accounted for 61 (49.2%), 42 (33.9%), 21 (16.9%) respec-
tively. From the total TB/HIV co-infected patients, 4
(3.2%) interrupted their TB treatment once.
The age distribution of TB/HIV co-infected and non-
co-infected patients was similar. Fifty percent of the co-
infected and 60.2% of the non-co-infected HIV patients
were females (P < 0.05). Higher proportion of co-infected
patients (43.5%) had no source of income compared to
the non-co-infected patients (26.7%) [OR = 1.9, (95%CI:
1.0, 3.8)]. After adjusting for confounding variables, co-
infected patients (57.5%) were more likely to have a lower
CD4 lymphocyte count than non-co-infected patients
(27.4%) [OR = 3.6; (95%CI: 2.1, 6.1)]. Before the diagnosis
of TB, significantly larger proportions (78.0%) of the co-
infected patients were in stage III of the WHO classifica-
tion compared to the non-co-infected HIV patients
(56.0%). All of the non-co-infected and 75.6% of the co-
infected patients were taking antiretroviral treatment
during the survey (Table-1).
The internal consistency of the Kessler 10 scale was
high (Cronbach's α = 0.93) and correlation between items
in the Kessler scale ranged from 0.50 to 0.79.
A lower CD4 lymphocyte count, a WHO stage of III
and IV, taking antiretroviral treatment, types of antiretro-
viral therapy, adherence to antiretroviral therapy, age, sex,
literacy and marital status were not significantly associ-
ated with CMD in the bivariate analysis. On the other
hand, occupation, source of income, TB/HIV co-infec-
tion, perceived stigma and perceived general health were
significantly associated with CMD in the bivariate analy-
sis and were therefore further evaluated in the multivari-
able model. Individuals who had no source of income
[OR = 1.7, (95%CI: 1.1, 2.8)], and day laborers [OR = 2.4,
95%CI: 1.2, 5.1)] were more likely to have CMD as com-
pared to individuals who had a source of income and gov-
ernment employees respectively. CMD was present in
63.7% of the TB/HIV co-infected patients and in 46.7% of
the non-co-infected patients. TB/HIV co-infected
patients were 1.7 times more likely to experience CMD
than the non-co-infected patients [OR = 1.7, (95%CI: 1.1,
2.9)]. Patients who perceived stigma [OR = 2.2, 95%CI:
1.5, 3.2)] and who rate their general health as "poor" [OR
= 10.0, 95%CI: 2.8, 35.1)] had significantly greater risk of
CMD than individual who did not perceive stigma or who
perceived their general health to be "good" (Table-2).
Discussion
We assessed the occurrence of CMD in TB/HIV co-
infected and non-co-infected patients using the Kessler
scale (K10)[28]. Caseness of CMD was assessed using a
cut-off point of 6/7 of the K10 which had a sensitivity and
specificity of specificity of 84.2% and 77.8% against the
psychiatrists' assessment using CPRS. Several studies
showed that the K10 had strong psychometric proper-
ties[32,34-36] and can discriminate between cases and
non-cases reported in the Diagnostic and Statistical Man-
ual of Mental Disorders (DSM-IV)[32,36]. In this study,
79 (64%) of the TB/HIV co-infected patients had CMD
which is higher than the findings of Hanlon et al (33%)
[28] and Tesfaye et al (40%)[28] among women in Ethio-
pia. The prevalence of depression among HIV seroposi-
tive women (19%) in the United States was also lower as
compared to our study[6]. The differences in prevalence
of mental disorders could be attributable to several fac-
tors including the population being studied, the study
periods and the diagnostic tools[29]. TB/HIV co-infected
patients were 1.7 times more likely to have CMD than
non-co-infected HIV patients. However, we did not find a
significant association between CD4 lymphocyte count
and CMD, which is consistent with several previous stud-
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Table 1: Socio-demographic and clinical characteristics of the study population in three hospitals of, Ethiopia, April, 2009
Variables TB/HIV coinfected patients HIV patients Crude OR Adjusted OR
Number (%) Number (%) (95%CI) (95%CI)
Age in Years
15-24 12(9.7) 42(9.1) 1 -
25-34 53(42.7) 221(47.5) 0.8(0.4,1.7)
> = 35 59(47.6) 202(43.4) 1.0(0.5,2.1)
Sex
Male 62(50) 185(39.8) 1.5(1.0, 2.2)* 1.9(1.0,3.7)*
Female 62(50) 280(60.2) 1 1
Educational status
Illiterate 30(24.2) 74(15.9) 1 1
literate 94(75.8) 391(84.1) 0.6(0.4, 0.9)* 0.8(0.4,1.6)
Marital status
Single 24(19.3) 75(16.1) 1.3(0.7,2.5) -
Married 42(33.9) 191(41.1) 0.9(0.5,1.6)
Divorced 33(26.6) 93(20.0) 1.5(0.8,2.7)
Widowed 25(20.2) 106(22.8) 1
Occupation (n = 580)
Government worker 17(14.8) 51(11.0) 1 1
Private employee 15(13.1) 83(17.8) 0.5(0.2,1.1) 0.9(0.3,2.7)
Merchant 1(0.9) 69(14.8) 0.4(0.2,1.0) 0.6(0.2,2.3)
Farmer 13(11.3) 32(6.9) 1.2(0.5,2.8) 2.0(0.6,6.5)
Housewives 15(13.0) 79(17.0) 0.6(0.3,1.3) 1.4(0.4,4.7)
Day laborers 22(19.1) 93(20.0) 0.7(0.4,1.5) 1.6(0.6,4.8)
No Job 32(27.8) 58(12.5) 1.6(1.1, 3.4)* 1.7(0.5,5.1)
Have source of income
Yes 70(56.5) 341(73.3) 1 1
No 54(43.5) 124(26.7) 2.2(1.4,3.2)* 1.9(1.0,3.8)*
WHO staging(n = 582)
Stage II 13(10.6) 136(29.6) 1 1
Stage III 96(78.0) 257(56.0) 1.6(1.3,1.9)* 2.3(1.1,4.6)*
Stage IV 14(11.4) 66(14.4) 1.2(0.9,1.5) 1.3(0.5,3.5)
CD4 lymphocyte count(n = 489)
< 200 46(57.5) 112(27.4) 1.9(1.2,2.8)* 3.6(2.1,6.1)*
> = 200 34(42.5) 297(72.6) 1 1
Antiretroviral therapy
Yes 93(75.6) 462(100) 0.02(0.001, 0.04) 0.01(0.001, 0.003)*
No 31(24.4) 3 1
*statistically significant (P < 0.05)
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Variables Common Mental Disorders Crude OR Adjusted OR
Yes (%) No (%) (95%CI) (95%CI)
Sex
Male 132(53.4) 115(46.6) 1
Female 164(48.0) 178(52.0) 0.8(0.5,1.1) -
Literacy status
Literate 236(48.7) 249(51.3) 1 -
Non-literate 60(57.7) 44(42.3) 1.4(0.9,2.2)
Age
15-24 21(38.9) 33(61.1) 1 -
25-35 145(52.9) 129(47.1) 1.7(0.9,3.2)
> = 35 130(49.8) 131(50.2) 1.5(0.8,2.8)
Marital status
Single 48(48.5) 51(51.5) 0.6(0.4,1.0) -
Married 106(45.5) 127(54.5) 0.5(0.4,0.9)
Divorced 65(51.6) 61(48.4) 0.8(0.5,1.2)
Widowed 77(58.8) 54(41.2) 1
Occupation
Government employee 23(33.8) 45(66.2) 1 1
Private employee 49(50.0) 49(50.0) 1.9(1.0, 3.7) * 2.2 (1.1,4.6)*
Merchant 35(44.3) 44(55.7) 1.5(0.8,3.0) 2.1 (1.0,4.4)*
Farmers 24(53.3) 21(46.7) 2.2(1.0, 4.8) * 1.8 (0.8,4.2)
Housewives 40(42.6) 54(57.4) 1.4(0.7,2.7) 1.2 (0.5,2.8)
Day Laborers 66(57.9) 48(42.1) 2.7(1.4, 5.0) * 2.4 (1.2, 5.1) *
Jobless 59(64.8) 32(35.2) 3.6(1.8, 6.9) * 2.5 (1.1,5.6) *
Have source of income
Yes 190(46.2) 221(53.8) 1 1
No 106(59.3) 72(40.7) 1.6(1.2,2.4) * 1.7(1.1,2.8) *
HIV/TB co-infection
No 217(46.7) 248(53.3) 1 1
Yes 79(63.7) 45(36.3) 2.0(1.3,3.0) * 1.7 (1.1,2.9) *
WHO staging(n = 582)
Stage II 73(49) 76(51) 1
Stage III 194(55.0) 159(45.0) 1.1(0.5, 1.2) -
Stage IV 24(30) 56(70) 0.8(0.7, 1.5)
CD4 lymphocyte count(n = 489)
< 200 74(46.8) 84(53.2) 1.2(0.8.1.7) -
> = 200 171(51.7) 160(48.3) 1
Taking antiretroviral therapy
Yes 274(49.4) 281(50.6) 1 -
No 22(64.7) 12(35.3) 1.8(0.9,3.8)
Adherence to antiretroviral therapy(ART)
Yes 285(49.7) 288(50.3) 1 -
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Page 6 of 8ies[37-39]. TB/HIV co-infected patients can be at higher
risk of CMD as a result of stigma and discrimination by
the society[5]. We also found out that perceived stigma
was one of the independent predictors of CMD. People
with perceived stigma may have a low self image and be
socially isolated which may predispose them to CMD[40].
Poverty is known to be a major risk factor for mental
health problems [3]. Many individuals in developing
countries suffer from CMD as a result of stress caused by
poverty[3,41]. In this study, daily labourers and jobless
individuals, both economically disadvantaged groups,
were at a higher risk of CMD. Use of the locally made
alcohol called "Katikala", which is common among daily
labourers in Ethiopia [42], can also predispose to CMD.
In contrast with other studies[3,40,43], we did not
observe a significant association between marital status,
gender and CMD.
In our study, the perception of poor general health was
strongly associated with CMD. However, there could be a
bi-directional relationship between perceived general
health and depression. Poor perceived general health
could have resulted from the presence of CMD.
Although antiretroviral drugs, particularly Efavirenz,
can cause CMD[4], our result did not show an association
between this drug and CMD. Adherence to antiretroviral
therapy has been reported to be affected by depres-
sion[4]. However, in our study we did not observe an
association between adherence and CMD.
Some methodological limitations need to be noted in
interpreting the findings of this study. First, the Kessler 10
scale is not 100% sensitive and specific and we might have
misdiagnosed or missed some cases of CMD. Second, no
detailed validation study was done for the stigma scale.
Third, 20% of the TB/HIV co-infected patients were lost
to follow-up which might introduce information bias.
Important risk factors of CMD such as substance and
alcohol use were not assessed.
Conclusions
TB/HIV co-infected patients were at higher risk of devel-
oping CMD than non-co-infected patients. Occupation,
perceived stigma and perceived general health were other
risk factors for CMD. TB/HIV control programs should
develop guidelines to screen and treat CMD among TB/
HIV co-infected patients. Screening programs should
focus on individuals with no source of income, jobless
people and day labourers. We recommend prospective
cohort study to investigate the cause effect relationship of
risk factors and CMD.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AD conceived and designed the study, analyzed the data and drafted the man-
uscript. MT participated in the design, conception and reviewed the article.
YH, GA and LA were involved in report writing and reviewing. LD and RC were
involved in analysis and critically reviewed the article. All authors read and
approved the final manuscript.
Acknowledgements
The authors acknowledge the HIV Prevention and Control Office (HAPCO) of 
the Oromiya regional state in Ethiopia for funding the study. The authors 
appreciate the study participants for their cooperation in providing the neces-
sary information.
Author Details
1Department of Epidemiology, Jimma University, Jimma, Ethiopia, 
2Department of Epidemiology and Social Sciences, Antwerp University, 
Antwerp, Belgium, 3Department of psychiatry, Jimma University, Jimma, 
Ethiopia, 4Department of Health Service management, Jimma University, 
Jimma, Ethiopia, 5Institute of Tropical Medicine, Antwerp, Belgium, 
6Department of Medical Laboratory Sciences and Pathology, Jimma University, 
Jimma, Ethiopia and 7Department of Physiology and Biometrics, Ghent 
University, Ghent, Belgium
References
1. Lopez AD, Mathers CD, Ezatti M, Jamison D, Murray C: Global burden of 
diseases and risk factors.  New York, Oxford University Press; 2006. 
Received: 19 March 2010 Accepted: 9 July 2010 
Published: 9 July 2010
This article is available from: http://www.biomedcentral.com/1471-2334/10/201© 2010 D r bew et a ; licensee BioMed Central Ltd. is an Open Access articl  distributed under h  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Dise s s 2010, 10:201
No 8(50) 8(50) 1.1(0.3,2.7)
ART regimen(n = 555)
Nevirapine based 179(48.5) 190(51.5) 1
Efavirenz based 95(51.1) 91(48.9) 1.1(0.7,1.5) -
Perceived Stigma
No 132(41.9) 183(58.1) 1 1
Yes 164(59.9) 110(40.1) 2.0(1.4,2.8)* 2.2(1.5,3.2)*
Perceived General Health
Good 168(39.4) 258(60.6) 1 1
Medium 102(76.1) 32(23.9) 4.8(3.1.7.6)* 4.7 (2.9,7.6) *
Poor 26(89.7) 3(10.3) 13.3(3.9,44.5)* 10.0 (2.8,35.1)*
*P-Value < 0.05
Table 2: Association of socio-demographic and clinical characteristics and CMD in three hospitals of Ethiopia (Continued)
Deribew et al. BMC Infectious Diseases 2010, 10:201
http://www.biomedcentral.com/1471-2334/10/201
Page 7 of 82. Patel V: Mental health in low- and middle-income countries.  Br Med Bull 
2007, 81-82:81-96.
3. WHO: Mental Health, New understanding, new hope: The world health 
report, WHO, 2001.   [http://www.who.int/whr/2001/en/].
4. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, Rahman A: No 
health without mental health.  Lancet 2007, 370(9590):859-877.
5. Li L, Lee SJ, Thammawijaya P, Jiraphongsa C, Rotheram-Borus MJ: Stigma, 
social support, and depression among people living with HIV in 
Thailand.  AIDS Care 2009, 21(8):1007-1013.
6. Morrison MF, Petitto JM, Ten Have T, Gettes DR, Chiappini MS, Weber AL, 
Brinker-Spence P, Bauer RM, Douglas SD, Evans DL: Depressive and 
anxiety disorders in women with HIV infection.  Am J Psychiatry 2002, 
159(5):789-796.
7. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London 
AS, Turner BJ, Eggan F, Beckman R, Vitiello B, et al.: Psychiatric disorders 
and drug use among human immunodeficiency virus-infected adults 
in the United States.  Arch Gen Psychiatry 2001, 58(8):721-728.
8. Maj M, Janssen R, Starace F, Zaudig M, Satz P, Sughondhabirom B, 
Luabeya MA, Riedel R, Ndetei D, Calil HM, et al.: WHO Neuropsychiatric 
AIDS study, cross-sectional phase I. Study design and psychiatric 
findings.  Arch Gen Psychiatry 1994, 51(1):39-49.
9. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, Barresi PJ, 
Coates TJ, Chesney MA, Buchbinder S: Risk factors for HIV infection 
among men who have sex with men.  Aids 2006, 20(5):731-739.
10. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener 
MM, Singh N: Adherence to protease inhibitor therapy and outcomes in 
patients with HIV infection.  Ann Intern Med 2000, 133(1):21-30.
11. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, Monforte 
AD, Wu AW, Starace F: Depressive symptoms, neurocognitive 
impairment, and adherence to highly active antiretroviral therapy 
among HIV-infected persons.  Psychosomatics 2004, 45(5):394-402.
12. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J: Sociodemographic 
and psychological variables influencing adherence to antiretroviral 
therapy.  Aids 1999, 13(13):1763-1769.
13. Leserman J: Role of depression, stress, and trauma in HIV disease 
progression.  Psychosom Med 2008, 70(5):539-545.
14. Ironson G, O'Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, 
Schneiderman N, Solomon G: Psychosocial factors predict CD4 and viral 
load change in men and women with human immunodeficiency virus 
in the era of highly active antiretroviral treatment.  Psychosom Med 
2005, 67(6):1013-1021.
15. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, 
Boland RJ, Moore J: Mortality, CD4 cell count decline, and depressive 
symptoms among HIV-seropositive women: longitudinal analysis from 
the HIV Epidemiology Research Study.  Jama 2001, 285(11):1466-1474.
16. Aydin IO, Ulusahin A: Depression, anxiety comorbidity, and disability in 
tuberculosis and chronic obstructive pulmonary disease patients: 
applicability of GHQ-12.  Gen Hosp Psychiatry 2001, 23(2):77-83.
17. Aghanwa HS, Erhabor GE: Demographic/socioeconomic factors in 
mental disorders associated with tuberculosis in southwest Nigeria.  J 
Psychosom Res 1998, 45(4):353-360.
18. Husain MO, Dearman SP, Chaudhry IB, Rizvi N, Waheed W: The 
relationship between anxiety, depression and illness perception in 
tberculosis patients in Pakistan.  Clin Pract Epidemiol Ment Health 2008, 
4:4.
19. Kruijshaar ME, Lipman M, Essink-Bot ML, Lozewicz S, Creer D, Dart S, 
Maguire H, Abubakar I: Health status of UK patients with active 
tuberculosis.  Int J Tuberc Lung Dis 14(3):296-302.
20. WHO: Global Tuberculosis control: Surveillance, planning and 
Financing. World Report 2008.   [http://www.who.int/tb/publications/
global_report/en/].
21. Aliyu MH, Salihu HM: Tuberculosis and HIV disease: two decades of a 
dual epidemic.  Wien Klin Wochenschr 2003, 115(19-20):685-697.
22. Maher D, Watt CJ, Williams BG, Raviglione M, Dye C: Tuberculosis deaths 
in countries with high HIV prevalence: what is their use as an indicator 
in tuberculosis programme monitoring and epidemiological 
surveillance?  Int J Tuberc Lung Dis 2005, 9(2):123-127.
23. Harries AD, Hargreaves NJ, Kemp J, Jindani A, Enarson DA, Maher D, 
Salaniponi FM: Deaths from tuberculosis in sub-Saharan African 
countries with a high prevalence of HIV-1.  Lancet 2001, 
357(9267):1519-1523.
24. Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high 
HIV prevalence populations in sub-Saharan Africa.  Aids 2001, 
15(2):143-152.
25. WHO: Stop TB Department and Department of HIV/AIDS. Interim 
policy on collaborative TB/HIV activities. WHO/HTM/TB/2004.330.  
2004.
26. Demissie MLB, Tegbaru B: Human Immunodeficiency virus (HIV) 
infection in tuberculosis patients in Addis Ababa. Ethiop.  
2000:277-282.
27. Kassu A, Mengistu G, Ayele B, Diro E, Mekonnen F, Ketema D, Moges F, 
Mesfin T, Getachew A, Ergicho B, et al.: Coinfection and clinical 
manifestations of tuberculosis in human immunodeficiency virus-
infected and -uninfected adults at a teaching hospital, northwest 
Ethiopia.  J Microbiol Immunol Infect 2007, 40(2):116-122.
28. Tesfaye M, Hanlon C, Wondimagegn D, Alem A: Detecting postnatal 
common mental disorders in Addis Ababa, Ethiopia: validation of the 
Edinburgh Postnatal Depression Scale and Kessler Scales.  J Affect 
Disord 122(1-2):102-108.
29. Hanlon C, Medhin G, Alem A, Araya M, Abdulahi A, Hughes M, Tesfaye M, 
Wondimagegn D, Patel V, Prince M: Detecting perinatal common mental 
disorders in Ethiopia: validation of the self-reporting questionnaire 
and Edinburgh Postnatal Depression Scale.  J Affect Disord 2008, 
108(3):251-262.
30. Deribew A, Tesfaye M, Hailmichael Y, Negussu N, Daba S, Wogi A, 
Belachew T, Apers L, Colebunders R: Tuberculosis and HIV co-infection: 
its impact on quality of life.  Health Qual Life Outcomes 2009, 7:105.
31. Ministry of Health, Ethiopia: TB, leprosy and TB/HIV prevention and 
control program, Manual. Addis Ababa, Ethiopia.  2008 [http://
www.moh.gov.et/].
32. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, 
Walters EE, Zaslavsky AM: Short screening scales to monitor population 
prevalences and trends in non-specific psychological distress.  Psychol 
Med 2002, 32(6):959-976.
33. Berger BE, Ferrans CE, Lashley FR: Measuring stigma in people with HIV: 
psychometric assessment of the HIV stigma scale.  Res Nurs Health 2001, 
24(6):518-529.
34. Donker T, Comijs H, Cuijpers P, Terluin B, Nolen W, Zitman F, Penninx B: 
The validity of the Dutch K10 and extended K10 screening scales for 
depressive and anxiety disorders.  Psychiatry Res 176(1):45-50.
35. Fassaert T, De Wit MA, Tuinebreijer WC, Wouters H, Verhoeff AP, Beekman 
AT, Dekker J: Psychometric properties of an interviewer-administered 
version of the Kessler Psychological Distress scale (K10) among Dutch, 
Moroccan and Turkish respondents.  Int J Methods Psychiatr Res 2009, 
18(3):159-168.
36. Furukawa TA, Kessler RC, Slade T, Andrews G: The performance of the K6 
and K10 screening scales for psychological distress in the Australian 
National Survey of Mental Health and Well-Being.  Psychol Med 2003, 
33(2):357-362.
37. Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, 
Brinker-Spence P, Job C, Mercer DE, Wang YL, et al.: Association of 
depression with viral load, CD8 T lymphocytes, and natural killer cells 
in women with HIV infection.  Am J Psychiatry 2002, 159(10):1752-1759.
38. Perry S, Fishman B, Jacobsberg L, Frances A: Relationships over 1 year 
between lymphocyte subsets and psychosocial variables among 
adults with infection by human immunodeficiency virus.  Arch Gen 
Psychiatry 1992, 49(5):396-401.
39. Rabkin JG, Williams JB, Remien RH, Goetz R, Kertzner R, Gorman JM: 
Depression, distress, lymphocyte subsets, and human 
immunodeficiency virus symptoms on two occasions in HIV-positive 
homosexual men.  Arch Gen Psychiatry 1991, 48(2):111-119.
40. Perlick DA, Rosenheck RA, Clarkin JF, Sirey JA, Salahi J, Struening EL, Link 
BG: Stigma as a barrier to recovery: Adverse effects of perceived stigma 
on social adaptation of persons diagnosed with bipolar affective 
disorder.  Psychiatr Serv 2001, 52(12):1627-1632.
41. Araya R, Rojas G, Fritsch R, Acuna J, Lewis G: Common mental disorders in 
Santiago, Chile: prevalence and socio-demographic correlates.  Br J 
Psychiatry 2001, 178:228-233.
42. Deribew A: Distribution of Most-at-risk Population Groups and their 
perceptions towards HIV/AIDS: A Baseline Survey in Amhara Region for 
the Implementation of Mobile HIV Counselling and Testing.  Bethesda, 
MD: Private Sector Program-Ethiopia, Abt Associates Inc; 2009. 
Deribew et al. BMC Infectious Diseases 2010, 10:201
http://www.biomedcentral.com/1471-2334/10/201
Page 8 of 843. Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, 
Demyttenaere K, de Girolamo G, Haro JM, Jin R, et al.: Cross-national 
associations between gender and mental disorders in the World 
Health Organization World Mental Health Surveys.  Arch Gen Psychiatry 
2009, 66(7):785-795.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/10/201/prepub
doi: 10.1186/1471-2334-10-201
Cite this article as: Deribew et al., Common mental disorders in TB/HIV co-
infected patients in Ethiopia BMC Infectious Diseases 2010, 10:201
